Showing results (191-200 of 408) with videos related to
Sort By:
Pageof 41
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 4, 2012
Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalitiesEsteban Braggio, Ahmet Dogan, Jonathan J Keats, et al.Cancer Research|April 23, 2009
Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphomaAnne J Novak, Susan L Slager, Zachary S Fredericksen, et al.Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopeniaGregory A Wiseman, Bryan R Leigh, William D Erwin, et al.Blood|July 15, 2004
Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcomeAnne J Novak, Deanna M Grote, Mary Stenson, et al.Mayo Clinic Proceedings|July 13, 2004
Clinical course of patients with relapsed multiple myelomaShaji K Kumar, Terry M Therneau, Morie A Gertz, et al.Haematologica|October 14, 2011
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphomaLuis F Porrata, Kay Ristow, Joseph P Colgan, et al.Haematologica|April 24, 2024
Monocyte response to SARS-CoV-2 protein ORF8 is associated with severe COVID-19 infection in patients with chronic lymphocytic leukemiaGordon J Ruan, Xiaosheng Wu, Kimberly A Gwin, et al.Blood|June 16, 2011
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphomaIvana N M Micallef, Matthew J Maurer, Gregory A Wiseman, et al.British Journal of Haematology|April 7, 2009
Risk of non-Hodgkin lymphoma in association with germline variation in complement genesJames R Cerhan, Anne J Novak, Zachary S Fredericksen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2005
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphomaThomas E Witzig, Susan M Geyer, Irene Ghobrial, et al.Pageof 41